Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aesgen, MGI, Zycos deal

Aesgen shareholders are eligible for $58 million in regulatory and sales milestones, plus and a 5% royalty.

Read the full 175 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE